189333-49-1

Basic information

• Product Name: 3-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE
• Synonyms: 3-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE;3,9-Diazaspiro[5.5]undecane, 3-(phenylmethyl)-;3-Benzyl-3,9-diazasprio[5,5undecane dihydrochloride;3,9-Diazaspiro[5.5]undecane,3-(phenylMethyl)- hydrochloride;3-benzyl-3,9-diazaspiro[5.5]undecane dihydrochloride
• CAS NO: 189333-49-1
• Molecular Formula: C₁₆H₂₄N₂
• Molecular Weight: 244.38
• Mol File: 189333-49-1.mol

Chemical Properties

• Boiling Point: 357.738 °C at 760 mmHg
• Flash Point: 135.985 °C
• Appearance: /
• Density: 1.057 g/cm³
• Vapor Pressure: 2.67E-05mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 11.02±0.20(Predicted)
• CAS DataBase Reference: 3-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE(189333-49-1)
• EPA Substance Registry System: 3-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE(189333-49-1)

Safety Data

• Hazardous Substances Data: 189333-49-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Benzyl-3,9-diaza-spiro[5.5]undecane is used as a chemical scaffold for the development of potential pharmaceutical agents due to its unique spirocyclic structure and the ability to modify the benzyl group for various biological activities.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-benzyl-3,9-diaza-spiro[5.5]undecane is utilized as a starting point for the synthesis of diverse drug candidates, leveraging its structural attributes to explore new therapeutic opportunities.
Used in Drug Discovery:
3-Benzyl-3,9-diaza-spiro[5.5]undecane is employed in drug discovery processes to create novel compounds with potential therapeutic effects, capitalizing on its capacity for chemical modification to enhance pharmacological properties.

InChI:InChI=1/C16H24N2/c1-2-4-15(5-3-1)14-18-12-8-16(9-13-18)6-10-17-11-7-16/h1-5,17H,6-14H2

Upstream product

• 1176981-06-8 1'-benzyl-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,4'-piperidine]-2,4,6,8-tetraone 
• 1176981-07-9 9-benzyl-3,9-diazaspiro[5.5]undecane-2,4-dione hydrochloride 
• 173405-78-2 tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate 
• 100-52-7 benzaldehyde 
• 929302-01-2 tert-butyl 9-benzyl-3,9-diazaspiro[5.5]undecane-3-carboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 189333-48-0 9-benzyl-3,9-diazaspiro[5.5]undecane-2,4-dione 
• 189333-46-8 9-benzyl-2,4-dioxo-3,9-diazaspiro[5,5]undecane-1,5-dicarbonitrile 

Downstream Products

• 1001054-49-4 3-benzyl-9-cyclobutyl-3,9-diazaspiro[5.5]undecane 
• 13323-40-5 3-benzyl-9-methyl-3,9-diaza-spiro[5.5]undecane 
• 929302-01-2 tert-butyl 9-benzyl-3,9-diazaspiro[5.5]undecane-3-carboxylate 
• 1171506-89-0 3-benzyl-3,9-diazaspiro[5.5]undecane dihydrochloride 
• 1338706-96-9 C₃₃H₃₉ClN₂O₅ 
• 180-46-1 3,9-diazaspiro[5,5]undecane 
• 173405-78-2 tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate 
• 1067902-24-2 4-(9-Benzyl-3,9-diazaspiro[5.5]undec-3-yl)-N-methylbenzamide 
• 867004-03-3 C₃₇H₄₁F₆N₃O 

Relevant articles and documents

Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents

A series of new 8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one(BTZ) derivatives containing a C-2 nitrogen spiro-heterocycle moiety based on the structures of BTZ candidates BTZ043 and PBTZ169 were designed and synthesized as new antitubercular agents. Many of them were found to have excellent in vitro activity (MIC 0.15 μM) against the drug susceptive Mycobacterium tuberculosis H37Rv strain and two clinically isolated multidrug-resistant strains. Compounds 11l and 11m display acceptable safety, greater aqueous solubility, and better pharmacokinetic profiles than PBTZ169, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.

3,9- DIAZASPIRO[5,5] UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS

Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Sepcifically, disclosed are a compound represented by fomula (I) and a pharmacologically acceptable salt thereof.

Preparation method of 3-alkyl-3, 9-diazaspiro [5, 5] undecane

The invention relates to a preparation method of 3-alkyl-3, 9-diazaspiro [5, 5] undecane. The preparation method comprises the following steps: a. reacting a compound I with cyanoacetate under the action of ammonia water and a catalyst to obtain a compoun

Polymorphism of novel spiroarylphosphine oxide

The invention relates to a polymorphic substance of a compound (2-((5-chloro-2-((2-methoxyl-4-(9-methyl-3,9-diaza-sprio[5.5]hendecane-3-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)dimethyl phosphineoxide (compound I). The invention further relates to a m

Preparation method, intermediate and crystal form of spironolamine arylphosphine oxide

The invention discloses a preparation method and a crystal form of high-purity spironolamine arylphosphine oxide. The invention further discloses a method for preparing a compound shown as a formula (I) and an intermediate compound.

Spiro aryl phosphorus oxide or sulfide

The invention discloses a spiro aryl phosphorus oxide or sulfide as ALK inhibitor, and in particular discloses a compound shown in a formula (I) as an ALK inhibitor or a pharmaceutically acceptable salt thereof.

CEPHEM COMPOUND HAVING CATECHOL GROUP

A compound of the formula: wherein X is -N=, -CH=, or the like; W is -CH2- or the like; U is -S- or the like; R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; R3/su

COMPOUNDS AND METHODS FOR PREPARING DIAZASPIRO DERIVATIVES

Compounds and methods are provided for the synthesis of diazaspiro derivatives of the Formula: wherein R is as described herein. Such compounds are useful, for example, as intermediates in the synthesis of biologically active compounds.

SUBSTITUTED AZASPIRO DERIVATIVES

Substituted azaspiro derivatives of the Formula:are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS

Spirocyclic sulfonamides and related compounds of Formula 1 are provided : (Formula (I)): in which the variables are as described herein. Such compounds may be used to modulate bradykinin receptor activity in vivo or in vitro, and are particularly useful